LXRX - Lexicon Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01 revenue of $0.04M misses by $0.01M
Lexicon Pharmaceuticals press release (NASDAQ:LXRX): Q1 GAAP EPS of -$0.16 beats by $0.01. Revenue of $0.04M (+33.3% Y/Y) misses by $0.01M. As of March 31, 2022, Lexicon had $86.5 million in cash and investments, as compared to $86.7 million as of December 31, 2021.
For further details see:
Lexicon Pharmaceuticals GAAP EPS of -$0.16 beats by $0.01, revenue of $0.04M misses by $0.01M